Evaluation of CpG Island Methylator Phenotype as a biomarker in colorectal cancer treated with adjuvant oxaliplatin

Lignende værker

• Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer
  af: Pectasides, Dimitrios, et al.
  Udgivet: (2015)
• Immune Response Gene Expression in Colorectal Cancer Carries Distinct Prognostic Implications According to Tissue, Stage and Site: A Prospective Retrospective Translational Study in the Context of a Hellenic Cooperative Oncology Group Randomised Trial
  af: Pentheroudakis, George, et al.
  Udgivet: (2015)
• The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastases
  af: Cohen, Stacey A., et al.
  Udgivet: (2017)
• Sample parameters affecting the clinical relevance of RNA biomarkers in translational breast cancer research
  af: Kotoula, Vassiliki, et al.
  Udgivet: (2012)
• Transcriptional Activity of Human Epidermal Growth Factor Receptor Family and Angiogenesis Effectors in Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma and Correlation with Patient Outcome
  af: Pentheroudakis, George, et al.
  Udgivet: (2009)